Search
Displaying 1–10 of 11 news results
-
Foundation Fighting Blindness and the Retinal Degeneration Fund
In 2018, the Foundation Fighting Blindness launched a venture philanthropy investment arm called the Retinal Degeneration (RD) Fund to help companies and researchers advance promising treatments for inherited retinal diseases into and through early-stage human studies. Currently, the RD Fund has allocated about 75% of its $72 million fund to eight investments.
-
Company formed with $8.15 million Series 1; led by founding investors Hatteras Venture Partners and the Foundation Fighting Blindness
-
Why Science Is Closer Than You Think To Beating Blindness
Using high-tech, camera-equipped eyeglasses and a healthy pair of eyes with 20/20 vision located hundreds, maybe even thousands, of miles away, a blind New York attorney has help to navigate the city’s busy streets and broken sidewalks.
-
People with disabilities are no different from anyone else. We all have strengths and challenges, and we all seek to be fully engaged in society. Treating blind people differently, either as incapable of conducting everyday tasks in life, or conversely, acting as though our ability to conduct even the most mundane chore is remarkable can be discouraging.
-
“It was important to me to make an everyday kid a hero”
Author Ben Shaberman talks to Optometry Today about how families affected by blindness helped to inspire his new novel, Retina Boy
-
Offer support to patients with inherited eye diseases
While genetic testing can direct treatment and identify those at risk, it is important to have support available when patients test positive.
-
Returning the favor: Never too late to give back as a premium surgeon
Whether local or international, through donation of services or funds, there is a way for everyone to give back.
-
A Retinal Research Nonprofit Paves the Way for Commercializing Gene Therapies
AN EMERGING, vision-restoring gene therapy for a devastating retinal disease is poised for Food and Drug Administration (FDA) approval. If it gets the regulatory nod, it will be the first gene therapy to receive FDA approval for the eye or an inherited condition.
-
The Challenge Continues: FFB Chairman Gordon Gund is Interviewed on CNBC
In a recent interview with CNBC’ s Brian Sullivan, during a tech-investor conference in Nantucket, Gordon explained why this is such a crucial time in retinal-research history.
